Fortress Biotech (FBIO)
(Real Time Quote from BATS)
$1.86 USD
+0.13 (7.51%)
Updated Aug 8, 2024 03:48 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 181 - 200 ( 317 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Partner Companies Push Forward; Significant Cash Flow Events on Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Recap - Journey Performing Well; Pipeline Gaining Momentum
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S